<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="NEW YORK, NY / ACCESSWIRE / March 11, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.” data-reactid=”12″>NEW YORK, NY / ACCESSWIRE / March 11, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Geron Corporation (GERN)” data-reactid=”13″>Geron Corporation (GERN)
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/geron-corporation-et-al-loss-submission-form?prid=5657&wire=1
Lead Plaintiff Deadline: March 23, 2020
Class Period: March 19, 2018 to September 26, 2018″ data-reactid=”14″>If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/geron-corporation-et-al-loss-submission-form?prid=5657&wire=1
Lead Plaintiff Deadline: March 23, 2020
Class Period: March 19, 2018 to September 26, 2018
The filed complaint alleges that defendants misled investors regarding a drug called imetelstat, which was intended to treat certain cancers that occur in bone marrow. Specifically, defendants misled investors about the results of a clinical drug study of imetelstat called IMbark. That study was designed to ascertain whether imetelstat helped patients with a cancer called myelofibrosis.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Beyond Meat, Inc. (BYND)” data-reactid=”16″>Beyond Meat, Inc. (BYND)
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/beyond-meat-inc-loss-submission-form?prid=5657&wire=1
Lead Plaintiff Deadline: March 30, 2020
Class Period: May 2, 2019 to January 27, 2020″ data-reactid=”17″>If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/beyond-meat-inc-loss-submission-form?prid=5657&wire=1
Lead Plaintiff Deadline: March 30, 2020
Class Period: May 2, 2019 to January 27, 2020
Allegations against BYND include that: (i) Beyond Meat’s termination of its supply agreement with Don Lee constituted a breach of that agreement, thus exposing the Company to foreseeable legal liability and reputational harm; (ii) Beyond Meat and certain of its employees had doctored and omitted material information from a food safety consultant’s report, which the Company represented as accurate to Don Lee; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Tilray, Inc. (TLRY)” data-reactid=”19″>Tilray, Inc. (TLRY)
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/tilray-inc-loss-submission-form?prid=5657&wire=1
Lead Plaintiff Deadline: May 5, 2020
Class Period: January 15, 2019 to March 2, 2020″ data-reactid=”20″>If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/tilray-inc-loss-submission-form?prid=5657&wire=1
Lead Plaintiff Deadline: May 5, 2020
Class Period: January 15, 2019 to March 2, 2020
Allegations against TLRY include that: (i) the purported advantages of the marketing and revenue sharing agreement with Authentic Brands Group (the “ABG Agreement”)were significantly overstated; (ii) the under performance of the ABG Agreement would foreseeably have a significant impact on the Company’s financial results; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.” data-reactid=”22″>To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]” data-reactid=”24″>CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="SOURCE: The Law Offices of Vincent Wong” data-reactid=”25″>SOURCE: The Law Offices of Vincent Wong
View source version on accesswire.com:
https://www.accesswire.com/580198/SHAREHOLDER-ALERT-GERN-BYND-TLRY-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines
Add Comment